It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...